COVID-19 vaccines and kidney disease.
Martin Windpessl,Annette Bruchfeld,Annette Bruchfeld,Hans-Joachim Anders,Holly Kramer,Holly Kramer,Meryl Waldman,Laurent Rénia,Lisa F. P. Ng,Zhou Xing,Andreas Kronbichler,Andreas Kronbichler +11 more
Reads0
Chats0
Abstract:
Patients with kidney diseases should be prioritized for COVID-19 vaccination and the available data suggest that replication-defective viral-vectored vaccines and mRNA vaccines are safe to use. As vaccine responses are likely to be lower in patients with kidney diseases than in the general population, highly potent vaccines should be preferred.read more
Citations
More filters
Journal ArticleDOI
Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: A prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine.
Julian Stumpf,Torsten Siepmann,Tom H. Lindner,Claudia Karger,Jörg Schwöbel,Leona Anders,Robert Faulhaber-Walter,Jens Schewe,Heike Martin,Holger Schirutschke,Kerstin Barnett,Jan Hüther,Petra Müller,Torsten Langer,Thilo Pluntke,Kirsten Anding-Rost,Frank Meistring,Thomas Stehr,Annegret Pietzonka,Katja Escher,Simon Cerny,Hansjörg Rothe,Frank Pistrosch,Harald Seidel,Alexander Paliege,Joachim Beige,Joachim Beige,Ingolf Bast,Anne Steglich,Florian Gembardt,Friederike Kessel,Hannah Kröger,Patrick Arndt,Jan Sradnick,Kerstin Frank,Anna Klimova,René Mauer,Xina Grählert,Moritz Anft,Arturo Blazquez-Navarro,Timm H. Westhoff,Ulrik Stervbo,Torsten Tonn,Torsten Tonn,Nina Babel,Nina Babel,Christian Hugo +46 more
TL;DR: In this paper, a prospective study explored the eight week time course of specific cellular (interferon-I³ release assay and flow cytometry) or/and humoral immune responses (ELISA) to SARS-CoV-2 boost vaccination in more than 3100 participants including medical personnel, dialysis patients and kidney transplant recipients using mRNA vaccines BNT162b2 or mRNA-1273.
Journal ArticleDOI
Haemodialysis patients show a highly diminished antibody response after COVID-19 mRNA vaccination compared to healthy controls.
Benedikt Simon,Harald Rubey,Andreas Treipl,Martin Gromann,Boris Hemedi,Sonja Zehetmayer,Bernhard Kirsch +6 more
TL;DR: In this article, a prospective cohort study that contained a group of 81 HD patients and 80 healthy controls was conducted, where the anti-SARS-CoV-2 S antibody response was measured for all participants 21 days after the second dose.
Journal ArticleDOI
Humoral and Cellular Responses to mRNA-1273 and BNT162b2 SARS-CoV-2 Vaccines Administered to Hemodialysis Patients.
José Jesús Broseta,Diana Rodríguez-Espinosa,Néstor Rodríguez,Maria Mar Mosquera,Maria Angeles Marcos,Natalia Egri,Mariona Pascal,Erica Soruco,José Luis Bedini,Beatriu Bayés,Francisco Maduell +10 more
TL;DR: In this paper, the authors evaluated the humoral and cellular responses to messenger RNA (mRNA) SARS-CoV-2 vaccines in kidney failure patients who are receiving maintenance dialysis and found that 97.7% of 175 vaccinated patients who were seronegative at baseline developed a response.
Journal ArticleDOI
Review of Early Immune Response to SARS-CoV-2 Vaccination Among Patients With CKD.
Edward J. Carr,Andreas Kronbichler,Matthew P M Graham-Brown,Graham Abra,Christos Argyropoulos,Lorraine Harper,Edgar V. Lerma,Rita S. Suri,Joel M. Topf,Michelle Willicombe,Swapnil Hiremath +10 more
TL;DR: In this article, the authors synthesized published studies and preprints evaluating surrogate measures of immunity after SARS-CoV-2 vaccination in patients with chronic kidney disease (CKD), including those receiving dialysis or with a kidney transplant.
Journal ArticleDOI
Humoral Response to SARS-CoV-2-Vaccination with BNT162b2 (Pfizer-BioNTech) in Patients on Hemodialysis
Michael Jahn,Johannes Korth,Oliver Dorsch,Olympia E. Anastasiou,Burkhard Sorge-Hädicke,Bartosz Tyczynski,Anja Gäckler,Oliver Witzke,Ulf Dittmer,Sebastian Dolff,Benjamin Wilde,Andreas Kribben +11 more
TL;DR: In this article, the authors measured humoral immune responses in 72 hemodialysis patients after standard vaccination with two doses of the mRNA-based SARS-CoV-2 vaccine BNT162b2 (Pfizer-BioNTech).
References
More filters
Journal ArticleDOI
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
Fernando P. Polack,Stephen J. Thomas,Nicholas Kitchin,Judith Absalon,Alejandra Gurtman,Stephen Lockhart,John L. Perez,Gonzalo Pérez Marc,Edson D. Moreira,Cristiano Zerbini,Ruth Bailey,Kena A. Swanson,Satrajit Roychoudhury,Kenneth Koury,Ping Li,Warren Kalina,David A. Cooper,Robert W. Frenck,Laura L. Hammitt,Özlem Türeci,Haylene Nell,Axel Schaefer,Serhat Ünal,Dina B. Tresnan,Susan Mather,Philip R. Dormitzer,Ugur Sahin,Kathrin U. Jansen,William C. Gruber +28 more
TL;DR: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older and safety over a median of 2 months was similar to that of other viral vaccines.
Journal ArticleDOI
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
Merryn Voysey,Clemens Sac.,Shabir A. Madhi,Lily Yin Weckx,P M Folegatti,Parvinder K. Aley,Brian Angus,Vicky L. Baillie,Shaun Barnabas,Q E Bhorat,S Bibi,Carmen Briner,P Cicconi,Andrea M. Collins,R Colin-Jones,Clare L. Cutland,Thomas C. Darton,Keertan Dheda,Duncan Cja.,Emary Krw.,Katie J. Ewer,Lee Fairlie,Saul N. Faust,Shuo Feng,Daniela M. Ferreira,Adam Finn,Anna Goodman,Catherine M. Green,Christopher A Green,Paul T. Heath,Christopher Hill,Helen Hill,Ian Hirsch,Hodgson Shc.,Allen Izu,S Jackson,D Jenkin,Joe Ccd.,S Kerridge,Anthonet Koen,Gaurav Kwatra,Rajeka Lazarus,Alison M. Lawrie,A Lelliott,Vincenzo Libri,Patrick J. Lillie,R Mallory,Mendes Ava.,Eveline Pipolo Milan,Angela M. Minassian,Alastair McGregor,Hazel Morrison,Y Mujadidi,Amit J Nana,P J O’Reilly,S D Padayachee,A Pittella,E Plested,Katrina M Pollock,M N Ramasamy,S Rhead,Alexandre Vargas Schwarzbold,Nisha Singh,Andrew Smith,R Song,Matthew D. Snape,Eduardo Sprinz,Rebecca K. Sutherland,R Tarrant,E. Thomson,M E Török,Mark Toshner,Turner Dpj.,Johan Vekemans,Tonya Villafana,Watson Mee.,C J Williams,Alexander D. Douglas,Hill Avs.,Teresa Lambe,Sarah C. Gilbert,Andrew J. Pollard +81 more
TL;DR: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials.
Journal ArticleDOI
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
Lindsey R. Baden,Hana M. El Sahly,Brandon Essink,Karen L. Kotloff,Sharon E. Frey,Rick Novak,David Diemert,Stephen A. Spector,Nadine Rouphael,C. Buddy Creech,John W McGettigan,Shishir Khetan,Nathan Segall,Joel Solis,Adam Brosz,Carlos Fierro,Howard J. Schwartz,Kathleen M. Neuzil,Lawrence Corey,Peter B. Gilbert,Holly Janes,Dean Follmann,Mary A. Marovich,John R. Mascola,Laura Polakowski,Julie E. Ledgerwood,Barney S. Graham,Hamilton Bennett,Rolando Pajon,Conor Knightly,Brett Leav,Weiping Deng,Honghong Zhou,Shu Liang Han,Melanie Ivarsson,Jacqueline Miller,Tal Z Zaks +36 more
TL;DR: The mRNA-1273 vaccine as discussed by the authors is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19.
Journal ArticleDOI
Immunological considerations for COVID-19 vaccine strategies.
Mangalakumari Jeyanathan,Sam Afkhami,Fiona Smaill,Matthew S. Miller,Brian D. Lichty,Zhou Xing +5 more
TL;DR: The immunological principles that need to be taken into consideration in the development of COVID-19 vaccine strategies are discussed and their strengths and potential shortfalls are examined, and inferences about their chances of success are made.
Journal ArticleDOI
SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates.
TL;DR: This Review discusses what is currently known about human humoral and cellular immune responses to severe acute respiratory syndrome coronavirus 2 and relates this knowledge to the COVID-19 vaccines currently in phase 3 clinical trials.
Related Papers (5)
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
Fernando P. Polack,Stephen J. Thomas,Nicholas Kitchin,Judith Absalon,Alejandra Gurtman,Stephen Lockhart,John L. Perez,Gonzalo Pérez Marc,Edson D. Moreira,Cristiano Zerbini,Ruth Bailey,Kena A. Swanson,Satrajit Roychoudhury,Kenneth Koury,Ping Li,Warren Kalina,David A. Cooper,Robert W. Frenck,Laura L. Hammitt,Özlem Türeci,Haylene Nell,Axel Schaefer,Serhat Ünal,Dina B. Tresnan,Susan Mather,Philip R. Dormitzer,Ugur Sahin,Kathrin U. Jansen,William C. Gruber +28 more
Humoral Response to the Pfizer BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis.
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
Lindsey R. Baden,Hana M. El Sahly,Brandon Essink,Karen L. Kotloff,Sharon E. Frey,Rick Novak,David Diemert,Stephen A. Spector,Nadine Rouphael,C. Buddy Creech,John W McGettigan,Shishir Khetan,Nathan Segall,Joel Solis,Adam Brosz,Carlos Fierro,Howard J. Schwartz,Kathleen M. Neuzil,Lawrence Corey,Peter B. Gilbert,Holly Janes,Dean Follmann,Mary A. Marovich,John R. Mascola,Laura Polakowski,Julie E. Ledgerwood,Barney S. Graham,Hamilton Bennett,Rolando Pajon,Conor Knightly,Brett Leav,Weiping Deng,Honghong Zhou,Shu Liang Han,Melanie Ivarsson,Jacqueline Miller,Tal Z Zaks +36 more
COVID-19 vaccine BNT162b1 elicits human antibody and T H 1 T cell responses.
Ugur Sahin,Alexander Muik,Evelyna Derhovanessian,Isabel Vogler,Lena M. Kranz,Mathias Vormehr,Alina Baum,Kristen E. Pascal,Jasmin Quandt,Daniel Maurus,Sebastian Brachtendorf,Verena Lörks,Julian Sikorski,Rolf Hilker,Dirk Becker,Ann Kathrin Eller,Jan Grützner,Carsten Boesler,Corinna Rosenbaum,Marie Cristine Kühnle,Ulrich Luxemburger,Alexandra Kemmer-Brück,David J. Langer,Martin Bexon,Stefanie Bolte,Katalin Karikó,Tania Palanche,Boris Fischer,Armin Schultz,Pei Yong Shi,Camila R. Fontes-Garfias,John L. Perez,Kena A. Swanson,Jakob Loschko,Ingrid L. Scully,Mark Cutler,Warren Kalina,Christos A. Kyratsous,David A. Cooper,Philip R. Dormitzer,Kathrin U. Jansen,Özlem Türeci +41 more